In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR Diane Balin-GauthierJean-Pierre DelordCuider Allal Original Article 01 December 2005 Pages: 709 - 718
4,4′-Dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007): a topical treatment for cutaneous metastases from malignant cancers David EilenderPatricia LoRussoLee Roy Morgan Original Article 24 September 2005 Pages: 719 - 726
Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours Iñaki F. TrocònizMaría J. GarridoRosendo Obach Original Article 28 October 2005 Pages: 727 - 735
A phase I combination chemotherapy study of biweekly paclitaxel and S-1 administration in patients with advanced gastric cancer Shuichi HokitaTakashi AikouSonshin Takao Original Article 15 September 2005 Pages: 736 - 740
Inhibition of cytokinesis and akt phosphorylation by chaetoglobosin K in ras-transformed epithelial cells Diane F. MatesicKimberly N. VillioHorace G. Cutler Original Article 28 October 2005 Pages: 741 - 754
A phase I study of 3-day topotecan and cisplatin in elderly patients with small-cell lung cancer Keiichi FujiwaraHiroshi UeokaMitsune Tanimoto Original Article 06 October 2005 Pages: 755 - 760
Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases Lucy LeeSunil SharmaPaul M. J. McSheehy Original Article 20 September 2005 Pages: 761 - 771
Long intracellular retention of 4′-thio-arabinofuranosylcytosine 5′-triphosphate as a critical factor for the anti-solid tumor activity of 4′-thio-arabinofuranosylcytosine Hitoshi SomeyaWilliam R. WaudWilliam B. Parker Original Article 23 September 2005 Pages: 772 - 780
Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters Goli SamimiStephen B. Howell Original Article 17 September 2005 Pages: 781 - 788
A phase I clinical trial of 12- O-tetradecanoylphorbol-13-acetate for patients with relapsed/refractory malignancies Dale SchaarLauri GoodellRoger K. Strair Original Article 18 October 2005 Pages: 789 - 795
Second-line chemotherapy in small cell lung cancer in a modified administration of topotecan combined with paclitaxel: a phase II study G. P. StathopoulosCh. ChristodoulouK. Katis Original Article 02 September 2005 Pages: 796 - 800
The effect of cytostatic drug treatment on intestine-specific transcription factors Cdx2, GATA-4 and HNF-1α in mice Barbara A. E. de KoningDicky J. Lindenbergh-KortleveAlexandra W. C. Einerhand Original Article 15 September 2005 Pages: 801 - 810
In vivo antitumor efficacy and cardiotoxicity of novel anthracycline ID6105 (11-hydroxy-aclacinomycin X, Hyrubicin) Jung Su RyuHong Sub LeeTae Yong Kim Original Article 21 September 2005 Pages: 811 - 818
The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice Rogier R. PressTessa BuckleOlaf van Tellingen Original Article 15 September 2005 Pages: 819 - 825
Pharmacodynamic properties of methotrexate and AminotrexateTM during weekly therapy Peter D. ColeMaría José AlcarazBarton A. Kamen Original Article 17 September 2005 Pages: 826 - 834
Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy? E. MarcuelloA. AltésM. Baiget Original Article 27 September 2005 Pages: 835 - 840
